Researchers have, for the first time, pinpointed the molecular changes in the brain that explain how ketamine rapidly alleviates symptoms of treatment-resistant depression. A study published on March 5, 2026, in the journal Molecular Psychiatry details the mechanism behind the drug’s fast-acting antidepressant effects.
The research, led by physiologist Takuya Takahashi from the Yokohama City University Graduate School of Medicine in Japan, involved collaboration with scientists at Keio University School of Medicine. The team used advanced brain imaging techniques to observe molecular changes in the brains of patients with treatment-resistant depression. This discovery offers novel hope for individuals who don’t respond to traditional depression treatments, a significant public health concern.
Siga o canal do Correio no WhatsApp e receba as principais notícias do dia no seu celular
For years, the precise way ketamine works in the human brain has remained a mystery, despite its known ability to quickly reduce depressive symptoms. The new study addresses this gap in understanding.
According to the research team, the key lies in proteins called AMPA receptors, which are crucial for communication between neurons and play a vital role in brain plasticity.
To investigate this phenomenon, the researchers utilized positron emission tomography (PET) imaging with a newly developed tracer, [¹¹C]K-2. This technology allowed them to visualize the distribution of AMPA receptors on the surface of brain cells in living humans in real-time.
The study analyzed data from three clinical trials conducted in Japan, involving 34 patients diagnosed with treatment-resistant depression and 49 healthy volunteers as a comparison group. Over two weeks, patients received intravenous infusions of ketamine or a placebo while undergoing brain imaging before and after treatment.
The results showed that individuals with treatment-resistant depression had alterations in AMPA receptor density in different brain regions. Following ketamine treatment, these structures underwent specific changes that directly correlated with symptom improvement.
The research observed an increase in receptor density in cortical areas linked to cognitive and emotional processing, while regions associated with the reward system – particularly the habenula, a structure in the diencephalon – showed a reduction in activity. This regional modulation was correlated with a decrease in depressive symptoms.
“The results confirm that the antidepressant action of ketamine is related to dynamic changes in these receptors,” said Takahashi. “We were able to visualize how the substance alters the distribution of AMPA receptors in specific brain regions and how these alterations accompany the clinical improvement of patients.”
Approximately 30% of people with major depression develop treatment-resistant depression, a condition where conventional antidepressants are ineffective. This study is particularly relevant because effective treatment options for these patients are limited.
The findings as well pave the way for advancements in personalized medicine. Researchers suggest that brain imaging focused on these receptors could turn into biomarkers capable of predicting which patients are most likely to respond to treatment.
Experts believe that understanding this mechanism could also accelerate the development of new medications with similar effects, but potentially safer and more targeted.
By demonstrating a direct link between AMPA receptor modulation and depression improvement in humans, the study bridges findings from basic research to clinical applications and may help redefine the future of depression treatment.
* Estagiária sob supervisão de Roberto Fonseca
Thamires Pinheiro*
Estagiário
Estagiária e formanda em Comunicação pela Universidade de Brasília (UnB). Transita entre a publicidade e o jornalismo, com textos e produção de conteúdo sobre Brasil, mundo, entretenimento e atualidades
